The U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a single sole source contract to the University of Arkansas System (Center for Translational Research in Aging and Longevity (CTRAL) at the University of Arkansas for Medical Sciences. 
This new requirement is to acquire specialized anti-inflammatory compounds that are proprietary to University of Virginia (UVA). The anti-inflammatory compounds from UVA will be optimized and developed using structure-based drug design. Information gained from in-vivo studies performed by UVA will be provided to WRAIR for structure-based drug design. WRAIR will use study results combined with x-ray crystallography studies performed by WRAIR to inform the design and synthesis of the next round of anti-inflammatory compounds.

This is a notice of intent to issue an award on the basis of other than full and open competition in accordance with the Federal Acquisition Regulation (FAR) 6.302-1 only one responsible source and no other supplies of services will satisfy agency requirements.